ClinicalTrials.gg
TerminatedNCT00091845Updated Jul 8, 2009

An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease

A Phase 1 interventional study of AVI-4020 Injection in West Nile Fever, sponsored by Sarepta Therapeutics, Inc.. Terminated. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-07-08.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Due to limited pool of eligble WNV patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Although the serious form of West Nile Virus (WNV) disease, referred to as neuroinvasive disease, is rare, it can result in permanent disabilities and occasionally death. For patients who get this serious form of WNV disease, there are no approved specific treatment options.

The purpose of this study is to test a new drug, AVI-4020 Injection, in patients who are hospitalized with recent symptoms of this form of WNV disease. In this study, we will determine if the AVI-4020 treatment is safe. This will be accomplished by reviewing the results of laboratory tests and clinical signs and symptoms. Additionally, we will review the patient data for signs that AVI-4020 is providing any beneficial effects against WNV neuroinvasive disease.

Read the detailed description
  1. To evaluate the safety of intravenously administered (IV) AVI-4020 Injection every 12 hours for a total of ten doses over the course of study surveillance.
  2. To evaluate the tolerability of intravenously administered AVI-4020 Injection every 12 hours for a total of ten doses over the course of study surveillance.
  3. To evaluate the effectiveness of intravenously administered AVI-4020 Injection at 45 mg every 12 hours for ten doses, based on the neurological status of each study Subject as measured by a combination of the NIH stroke scale score and the Glasgow coma scale score.
  4. To evaluate the robustness of the potential effectiveness of intravenously administered AVI-4020 Injection every 12 hours for ten doses over the course of 35 days of active surveillance, based on a variety of criteria, e.g., clinical, laboratory and/or neurophysiological results.
02

Conditions studied

  • West Nile Fever

Keywords

  • West Nile Fever Myelitis
  • West Nile Fever Encephalitis
  • West Nile Fever Meningitis
  • West Nile Fever Meningoencephalitis
03

In context

Lead sponsor

Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.

Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a positive serum or CSF ELISA MAC-IgM test indicating active/recent WNV infection, or the Subject resides in or has traveled to geographic areas with at least one of the following characteristics within the last seven days:

    1. Documented evidence of WNV infected mosquitoes or sentinel animals within the last 30 days
    2. Documented evidence of WNV infected dead animals within the last 30 days
    3. Documented human cases of WNV infection/disease within the last two weeks
  • Subject is between >18 and \<75 years of age.
  • Subject has developed a febrile disease with new neurological findings \<4 days prior to the current hospitalization.
  • Subject has had an oral temperature of >38 degrees Celsius within 48 hours of study entry.
  • Subject must have one or more of the following acute signs at the time of study entry:

    1. Signs of meningitis (nuchal rigidity)
    2. Signs of encephalitis (changes in mental status)
    3. Evidence of brainstem, cranial nerve, or cerebellar dysfunction
    4. Limb weakness.
  • Subject must have a CSF examination within 48 hours of study entry showing:

    1. Absence of any organisms on Gram or fungal stains
    2. White blood cell count of > 4 per mm3 (corrected for significant red blood cell contamination)
    3. Ratio of CSF glucose: plasma glucose of >0.40; and CSF protein >30 mg/dL
  • Subjects with must agree to practice adequate methods to protect themselves and their partners from conception as defined below:

    1. Men with reproductive potential are eligible to participate if they use an acceptable method of contraception (such as a condom with spermicide).
    2. Women with are eligible to participate if they are surgically sterile (via hysterectomy or bilateral tubal ligation) at least one year , or are using an acceptable method of contraception (such as oral, topical, or injected contraception, IUD, Nuva-Ring®, or double barrier method such as diaphragm and condom with spermicide).

Exclusion criteria

Exclusion Criteria:

  • Subject (or family or legal guardian) requests Do Not Resuscitate or Do Not Intubate orders.
  • Subject has multi-system organ failure at the time of screening or is not expected to survive the next 12 months due to another cause.
  • Subject has a history of any vaccine administration \<30 days prior to study entry.
  • Subject has a possible history of traumatic neuritis \<7 days prior to study entry (e.g., acupuncture, any needle-administered drugs, automobile accident, and/or blunt trauma).
  • Subject is female and is pregnant or breastfeeding. (If the Subject is not or has not been surgically sterilized, a negative serum pregnancy test is required within 72 hours prior to the administration of the first dose of study drug.)
  • Subject has any of the following abnormal laboratory results:

    1. Serum creatinine greater than 3.0 mg/dL or study Subject requires hemodialysis
    2. Liver function tests twice the
    3. Total level twice the upper limit of normal
    4. PT or twice the upper limit of normal
  • Documented presence of bacterial or non-WNV viral agents in CSF
  • Principal Investigator is of the opinion that the Subject's medical condition(s) or state of mental health would prevent adherence to protocol requirements or hinder interpretation of clinical study results.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Interventions

  • DrugAVI-4020 Injection
06

What researchers measure

Primary outcomes

  1. Safety and tolerability assessments will be based on evaluations of treatment emergent adverse events (TEAE), serious adverse events (SAE), serial clinical examinations, and serial conventional laboratory tests.

Secondary outcomes

  1. A secondary endpoint is the potential effectiveness of AVI-4020 Injection based on the neurological status measured by a combination of the NIH Stroke Scale and the Glasgow Coma Score (GCS).

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2004
First posted
Sep 21, 2004
Start
Nov 2004
CompletionActual
Nov 2004
Last update
Jul 8, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00091845
First posted
Sep 21, 2004
Start date
Nov 2004
Completion
Nov 2004
Last update
Jul 8, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion